Ferring appoints President of the Ferring Research Institute

Ferring appoints President of the Ferring Research Institute
02 April 2004 pulse

Ferring appoints President of the Ferring Research Institute

Lausanne, Switzerland – April 2, 2004 –

Ferring, a biopharmaceutical company with its headquarters in Lausanne, Switzerland announced today that Dr. John L. McGuire has been appointed as the President of the Ferring Research Institute.

Dr. McGuire joins Ferring after 25 years with Johnson & Johnson. His most recent position was Corporate Vice President of Business Development in Johnson & Johnson’s Pharmaceutical Group.

Dr. McGuire is an adjunct professor at the department of obstetrics, gynecology and reproductive sciences, University of Medicine and Dentistry of New Jersey, New Brunswick. He has published more than 200 scientific articles and edited several books.

Prior to his position as Corporate VP of Business Development, he held a variety of executive positions in R&D at Johnson & Johnson including Senior Vice President of Worldwide R&D at R.W. Johnson Pharmaceutical Research Institute. In addition to his R&D responsibilities, he was also responsible for identifying and in-licensing a number of important pharmaceutical products, notably erythropoietin.

Dr. McGuire has also held the position of Executive Director of Research at Ortho Pharmaceutical Corporation, a division of Johnson & Johnson. In this position he had responsibility for both drug discovery research as well as two independent clinical research and regulatory affairs units.

“We are delighted to welcome Dr. McGuire to the Ferring group” said Mr. Frederik Paulsen, Chairman of Ferring Group. “His experience and skills will ensure Ferring´s continued success in discovering interesting new compounds and bringing in new in-licensing opportunities, especially in the women’s health care area.”

About Ferring Pharmaceuticals

Ferring is a Swiss based research driven, speciality biopharmaceutical group active in global markets.  The company identifies, develops and markets innovative products in the areas of urology, obstetrics and infertility, gastroenterology and endocrinology.

In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in over 40 countries.

Please visit us at www.Ferring.com.

For more information, please contact

Sharmi Albrechtsen
Ferring International Center
+45 28 78 72 09

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.


Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.


Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals


Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.


Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.


Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.